Table 2.
Number and percentage of subjects with detectable CTL responses, by group
| Group | Protease | Integrase | |||
| Number of subjects with any response (%) | Mean responsea | Number of subjects with any response (%) | Mean responsea | ||
| Acute | Total | 7/28 (25) | 221 | 18/28 (64) | 378 |
| On therapyb | 3/17 (18) | --- | 9/17 (53) | --- | |
| Off therapyb | 4/13 (31) | --- | 10/13 (77) | --- | |
| Chronic | Total | 4/22 (18) | 204 | 15/22 (68) | 281 |
| On therapy | 2/13 (15) | --- | 9/13 (69) | --- | |
| Off therapy | 2/9 (22) | --- | 6/9 (67) | --- | |
| Controller | 2/6 (33) | 125 | 5/6 (83) | 215 | |
| Overall | 13/56 (23) | 212 | 38/56 (68) | 320 | |
a Values are SFC/million PBMC. b Two patients in the acute cohort were evaluated at two different time points, once on therapy, once off therapy.